Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. Its lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed for obesity and metabolic disease. Unlike many peers, Viking has a robust balance sheet with over $400 million in cash, no debt, and a clean equity structure, providing runway well into 2028.
The key catalyst over the next 12 months is the readout of Phase 2 data for VK2735 in obesity, expected in mid-2026. Early Phase 1 data showed impressive weight loss comparable to leading therapies like tirzepatide, with a favorable safety profile. Positive Phase 2 results could trigger a significant re-rating, partnership interest, or acquisition premium.
Viking also has a pipeline including VK0214 for X-ALD and VK2809 for NASH, providing additional upside optionality. The obesity market is projected to exceed $100 billion by 2030, and Viking’s oral formulation could capture a meaningful share if approved.
Risk Disclaimer: This is not financial advice. Investing in clinical-stage biotech stocks carries high risk, including regulatory setbacks, clinical trial failures, and dilution. Past performance does not guarantee future results. Always conduct your own due diligence.